59 related articles for article (PubMed ID: 2405644)
1. Adult onset nesidioblastosis: response of glucose, insulin, and secondary peptides to therapy with Sandostatin.
Mozell EJ; Woltering EA; O'Dorisio TM; Phillipson BE; Fletcher J; Fletcher WS; Howe B; Hill D; Rhea D
Am J Gastroenterol; 1990 Feb; 85(2):181-8. PubMed ID: 2405644
[TBL] [Abstract][Full Text] [Related]
2. Suppression of primary and secondary peptides with somatostatin analog in the therapy of functional endocrine tumors.
Woltering EA; Mozell EJ; O'Dorisio TM; Fletcher WS; Howe B
Surg Gynecol Obstet; 1988 Dec; 167(6):453-62. PubMed ID: 2460958
[TBL] [Abstract][Full Text] [Related]
3. Effect of somatostatin analog on peptide release and tumor growth in the Zollinger-Ellison syndrome.
Mozell E; Woltering EA; O'Dorisio TM; Fletcher WS; Sinclair AJ; Hill D
Surg Gynecol Obstet; 1990 Jun; 170(6):476-84. PubMed ID: 2188384
[TBL] [Abstract][Full Text] [Related]
4. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
[TBL] [Abstract][Full Text] [Related]
5. Prandial regulation of ghrelin secretion in humans: does glucagon contribute to the preprandial increase in circulating ghrelin?
Soule S; Pemberton C; Hunt P; Cole D; Raudsepp S; Inder W
Clin Endocrinol (Oxf); 2005 Oct; 63(4):412-7. PubMed ID: 16181233
[TBL] [Abstract][Full Text] [Related]
6. Observations on the effect of a somatostatin analog in the Zollinger-Ellison syndrome: implications for the treatment of apudomas.
Ellison EC; O'Dorisio TM; Sparks J; Mekhjian HS; Fromkes JJ; Woltering EA; Carey LC
Surgery; 1986 Aug; 100(2):437-44. PubMed ID: 2426819
[TBL] [Abstract][Full Text] [Related]
7. [Abnormal increase in pancreatic polypeptide in the secretin-provocation test: hypoglycemia-induced?].
Wirth HP; Eberle C; Gautschi K; Meyenberger C; Ammann R
Schweiz Med Wochenschr; 1995 Apr; 125(15):735-9. PubMed ID: 7740287
[TBL] [Abstract][Full Text] [Related]
8. Effect of octreotide on pancreatic endocrine function in partial pancreatectomy.
Presti M; Niehoff M; Rioux J; Burton F; Garvin P
J Surg Res; 1996 Mar; 61(2):449-53. PubMed ID: 8656623
[TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of SMS 201-995. Long-term treatment in gut neuroendocrine tumours, efficacy of oral administration, and possible use in non-tumoural inappropriate TSH hypersecretion.
Williams G; Anderson JV; Williams SJ; Bloom SR
Acta Endocrinol Suppl (Copenh); 1987; 286():26-36. PubMed ID: 2892335
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin analogue (SMS 201-995) in patients with gastrinomas.
Vinik AI; Tsai S; Moattari AR; Cheung P
Surgery; 1988 Nov; 104(5):834-42. PubMed ID: 2903562
[TBL] [Abstract][Full Text] [Related]
11. Enhanced glucose-dependent glucagon-like peptide-1 and insulin secretion in Crohn patients with terminal ileum disease is unrelated to disease activity or ileal resection.
Bendet N; Scapa E; Cohen O; Bloch O; Aharoni D; Ramot Y; Weiss M; Halevi A; Rapoport MJ
Scand J Gastroenterol; 2004 Jul; 39(7):650-6. PubMed ID: 15370686
[TBL] [Abstract][Full Text] [Related]
12. Medullary carcinoma of the thyroid, pancreatic nesidioblastosis and microadenosis, and pancreatic polypeptide hypersecretion: a new association and clinical and hormonal responses to long-acting somatostatin analog SMS 201-995.
Jerkins TW; Sacks HS; O'Dorisio TM; Tuttle S; Solomon SS
J Clin Endocrinol Metab; 1987 Jun; 64(6):1313-9. PubMed ID: 2883196
[TBL] [Abstract][Full Text] [Related]
13. Calcium reverses octreotide inhibition of insulin and glucagon levels in patients with insulinoma and glucagonoma.
Thompson CS; O'Dorisio TM; Woltering EA
Digestion; 1996; 57 Suppl 1():62-8. PubMed ID: 8813473
[TBL] [Abstract][Full Text] [Related]
14. Treatment of severe reactive hypoglycemia with a somatostatin analogue (SMS 201-995).
Lehnert H; Beyer J; Weber P; Krause U; Schrezenmeir J
Arch Intern Med; 1990 Nov; 150(11):2401-2. PubMed ID: 2241454
[TBL] [Abstract][Full Text] [Related]
15. Treatment of psoriasis with chronic subcutaneous administration of somatostatin analog 201-995 (sandostatin). II. Effect on pancreatic and thyroid hormone.
Camisa C; Schacht GE; O'Dorisio TM; Maceyko RF
Cleve Clin J Med; 1990; 57(1):77-81. PubMed ID: 2407389
[TBL] [Abstract][Full Text] [Related]
16. The effects of SMS 201-995 (sandostatin) on metabolic profiles in insulin-dependent diabetes mellitus.
Grossman LD; Shumak SL; George SR; Singer W; Zinman B
J Clin Endocrinol Metab; 1989 Jan; 68(1):63-7. PubMed ID: 2642488
[TBL] [Abstract][Full Text] [Related]
17. Effect of somatostatin analogue (SMS 201-995, Sandostatin) on pancreatic secretion in humans.
Creutzfeldt W; Lembcke B; Fölsch UR; Schleser S; Koop I
Am J Med; 1987 May; 82(5B):49-54. PubMed ID: 2884879
[TBL] [Abstract][Full Text] [Related]
18. Normalization of glucose homeostasis by a long-acting somatostatin analog SMS 201-995 in a newborn with nesidioblastosis.
Bruining GJ; Bosschaart AN; Aarsen RS; Lamberts SW; Sauer PJ; Del Pozo E
Acta Endocrinol Suppl (Copenh); 1986; 279():334-9. PubMed ID: 2877536
[TBL] [Abstract][Full Text] [Related]
19. Effect of the somatostatin analogue sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men.
Lembcke B; Creutzfeldt W; Schleser S; Ebert R; Shaw C; Koop I
Digestion; 1987; 36(2):108-24. PubMed ID: 2883060
[TBL] [Abstract][Full Text] [Related]
20. Postprandial effects of SMS 201-995 on gut hormones and glucose tolerance.
Williams G; Fuessl H; Kraenzlin M; Bloom SR
Scand J Gastroenterol Suppl; 1986; 119():73-83. PubMed ID: 2876509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
